IMARA Inc. (IMRA)
| Market Cap | 95.28M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -47.36M |
| Shares Out | 17.72M |
| EPS (ttm) | -2.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 78,893 |
| Open | 3.63 |
| Previous Close | 3.63 |
| Day's Range | 3.51 - 3.70 |
| 52-Week Range | 3.51 - 29.92 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 24.00 (+566.7%) |
| Est. Earnings Date | Nov 4, 2021 |
About IMRA
IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, an oral, once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for IMARA Inc. stock is "Strong Buy." The 12-month stock price forecast is 24.00, which is an increase of 566.67% from the latest price.
News
Imara to Participate in Upcoming Investor Conferences
SVB Leerink CybeRx Series and 2021 Cantor Virtual Global Healthcare Conference SVB Leerink CybeRx Series and 2021 Cantor Virtual Global Healthcare Conference
Imara to Present at Upcoming Investor Conferences
Citi 16th Annual BioPharma Virtual Conference, H.C. Wainwright 23rd Annual Global Investment Conference and Morgan Stanley 19th Annual Global Healthcare Conference Citi 16th Annual BioPharma Virtual Con...
Imara Reports Second Quarter 2021 Financial Results and Business Highlights
Accelerated enrollment in Phase 2b trials in sickle cell disease and beta-thalassemia; interim analyses expected in fourth quarter of 2021
Imara Announces Completion of Patient Enrollment in Ardent Phase 2b Clinical Trial of IMR-687 (tovinontrine) for Sick...
Interim analysis expected in fourth quarter of 2021 and primary endpoint readout now expected in first quarter of 2022 Interim analysis expected in fourth quarter of 2021 and primary endpoint readout no...
Imara to Webcast Conference Call of Second Quarter 2021 Financial Results and Business Highlights
BOSTON, July 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering...
Imara Raises $50M In Equity Funding To Support Development Of Sickle Cell Treatment Candidate
Imara Inc (NASDAQ: IMRA) has priced its previously announced underwritten public offering of shares at $6.00 per share for gross proceeds of $50 million. The offering will close by July 16.
Imara Announces Pricing of Public Offering
BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat pa...
Imara Announces Launch of Proposed Public Offering
BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat pa...
Biotech Losers In 2021 That Could Bounce Big In The Second Half
Biotech stocks are tricky investment bets that require careful analysis and scrutiny. A stock that has fallen off a cliff in reaction to a binary event can neither be written off entirely nor picked as ...
Imara Announces Recipients of the Second Annual Real Impact Grants Program to Support People Affected by Rare Genetic...
Imara has continued and expanded the program to award 30 grants totaling $150,000 to fund nonprofit, community-based organizations supporting individuals with sickle cell disease and beta-thalassemia Im...
Imara Presents Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Co...
Final data from 93-patient Phase 2a clinical trial show lower annualized rate of vaso-occlusive crises (VOCs) and longer time to first VOC on IMR-687
2 Falling Knives to Catch
Unexpectedly, Wall Street recommends acquiring shares of Protara Therapeutics Inc ( TARA , Financial) and IMARA Inc ( IMRA , Financial), despite the fact that these two equities have shown poor performa...
Imara to Present Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual ...
Oral presentation provides final results from 93-patient Phase 2a trial and additional interim data from open label extension trial
Imara Reports First Quarter 2021 Financial Results and Business Highlights
On-track to report interim analyses for both Ardent sickle cell disease and Forte beta-thalassemia Phase 2b clinical trials in the second half of 2021
Imara to Webcast Conference Call of First Quarter 2021 Financial Results and Business Highlights
BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering ...
Imara Opens Applications for the Second-Annual ‘Real Impact' Community Support Program to Address Unmet Needs Affecti...
Company will award grants totaling up to $150,000 to nonprofit community-based organizations that support sickle cell disease and beta-thalassemia patients and families Company will award grants totalin...
SHAREHOLDER ALERT: Investigation of IMARA Inc. Announced by Holzer & Holzer, LLC
Atlanta, Georgia--(Newsfile Corp. - March 22, 2021) - Holzer & Holzer, LLC is investigating whether IMARA Inc. ("IMARA" or the "Company") (NASDAQ: IMRA) complied with federal securities laws. On March 5...
Imara Announces Opening of Higher Dose Arms in Global Phase 2b Clinical Trials of IMR-687 for Sickle Cell Disease and...
Independent Data Monitoring Committees endorse opening higher dose IMR-687 treatment arms in ongoing Ardent and Forte Phase 2b clinical trials after review of safety and tolerability data at lower doses
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of IMARA, Inc. - IMRA
New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of IMARA, Inc. ("IMARA" or the "Company") (NASDAQ: IMRA). Such investors are advised ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of IMARA, Inc. - IMRA
NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of IMARA, Inc. ("IMARA" or the "Company") (NASDAQ: IMRA). Such investors are advised to contact R...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of IMARA, Inc. - IMRA
NEW YORK, March 10, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of IMARA, Inc. ("IMARA" or the "Company") (NASDAQ: IMRA). Such investors are advised to contact Rob...
Imara Reports Full Year 2020 Financial Results and Business Highlights
Significant progress advancing IMR-687 as an oral, once-a-day potentially disease modifying treatment for sickle cell disease and beta-thalassemia
Imara to Webcast Conference Call of Full Year 2020 Financial Results and Business Highlights
BOSTON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering...
Imara to Present at SVB Leerink 10th Annual Global Healthcare Conference
BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering...
Imara Announces the Appointment of Kenneth Attie, M.D. as Chief Medical Officer
Brings 30 years of medical research experience within the biopharmaceutical industry, including Acceleron Pharma and Genentech Brings 30 years of medical research experience within the biopharmaceutical...